159 related articles for article (PubMed ID: 21518929)
1. Recombinant interferon-α may retard progression of early primary myelofibrosis: a preliminary report.
Silver RT; Vandris K; Goldman JJ
Blood; 2011 Jun; 117(24):6669-72. PubMed ID: 21518929
[TBL] [Abstract][Full Text] [Related]
2. The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis.
Silver RT; Barel AC; Lascu E; Ritchie EK; Roboz GJ; Christos PJ; Orazi A; Hassane DC; Tam W; Cross NCP
Cancer; 2017 Jul; 123(14):2680-2687. PubMed ID: 28518222
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups.
Ianotto JC; Boyer-Perrard F; Gyan E; Laribi K; Cony-Makhoul P; Demory JL; De Renzis B; Dosquet C; Rey J; Roy L; Dupriez B; Knoops L; Legros L; Malou M; Hutin P; Ranta D; Schoenwald M; Andreoli A; Abgrall JF; Kiladjian JJ
Br J Haematol; 2013 Sep; 162(6):783-91. PubMed ID: 23848933
[TBL] [Abstract][Full Text] [Related]
4. Acute myelofibrosis: response to recombinant human interferon alpha-2a.
List AF; Kummet TD; Kerr DM
Leuk Res; 1990; 14(4):321-6. PubMed ID: 2332985
[TBL] [Abstract][Full Text] [Related]
5. Recombinant interferon alpha (rIFN alpha-2b) may retard progression of early primary myelofibrosis.
Silver RT; Vandris K
Leukemia; 2009 Jul; 23(7):1366-9. PubMed ID: 19440212
[No Abstract] [Full Text] [Related]
6. Reversible bone marrow aplasia induced by pegylated interferon-α-2a therapy in a patient with primary myelofibrosis.
Mainali NR; Bhatt VR; Kedia S; Krishnamurthy J; Wake LM; Akhtari M
J Oncol Pharm Pract; 2014 Oct; 20(5):386-92. PubMed ID: 24067929
[TBL] [Abstract][Full Text] [Related]
7. Interferon-alpha-2 in the treatment of idiopathic myelofibrosis.
Seewann HL; Gastl G; Lang A; Abbrederis K; Thaler J; Flener R; Huber C
Blut; 1988 Apr; 56(4):161-3. PubMed ID: 3355903
[TBL] [Abstract][Full Text] [Related]
8. Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013.
Silver RT; Peterson BL; Szatrowski TP; Powell BL; Stock W; Carroll AJ; Bloomfield CD; Schiffer CA; Larson RA
Leuk Lymphoma; 2003 Jan; 44(1):39-48. PubMed ID: 12691141
[TBL] [Abstract][Full Text] [Related]
9. A pilot study of recombinant human interleukin-4 therapy of myelofibrosis.
Giles FJ; Keating AR; Kurzrock R; Talpaz M
J Interferon Cytokine Res; 1999 Nov; 19(11):1253-5. PubMed ID: 10574617
[TBL] [Abstract][Full Text] [Related]
10. Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study.
Ianotto JC; Chauveau A; Boyer-Perrard F; Gyan E; Laribi K; Cony-Makhoul P; Demory JL; de Renzis B; Dosquet C; Rey J; Roy L; Dupriez B; Knoops L; Legros L; Malou M; Hutin P; Ranta D; Benbrahim O; Ugo V; Lippert E; Kiladjian JJ
Haematologica; 2018 Mar; 103(3):438-446. PubMed ID: 29217781
[TBL] [Abstract][Full Text] [Related]
11. Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial.
Gowin K; Jain T; Kosiorek H; Tibes R; Camoriano J; Palmer J; Mesa R
Leuk Res; 2017 Mar; 54():73-77. PubMed ID: 28113109
[TBL] [Abstract][Full Text] [Related]
12. Alpha interferon in the treatment of symptomatic myelofibrosis with myeloid metaplasia.
Parmeggiani L; Ferrant A; Rodhain J; Michaux JL; Sokal G
Eur J Haematol; 1987 Sep; 39(3):228-32. PubMed ID: 3678474
[TBL] [Abstract][Full Text] [Related]
13. Recombinant interferon-alpha-2b treatment of hairy-cell leukaemia: experience with a low-dose schedule.
Hasselbalch H; Braide I; Lisse I; Röckert LL; Swolin B; Carneskog J; Hagberg H; Hippe E; Jensen MK; Lundin P
Eur J Haematol; 1988 Nov; 41(5):438-44. PubMed ID: 3061836
[TBL] [Abstract][Full Text] [Related]
14. Intralesional alpha interferon therapy in papillary superficial transitional cell carcinoma of the bladder. A pilot study.
Di Stasi SM; Virgili G; Vespasiani G; Porena M; Micali F
Br J Urol; 1993 Apr; 71(4):422-6. PubMed ID: 8499986
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of recombinant alpha-interferon in malignant melanoma.
Neefe JR; Legha SS; Markowitz A; Salmon S; Meyskens F; Groopman J; Campion M; Evans L
Am J Clin Oncol; 1990 Dec; 13(6):472-6. PubMed ID: 2239801
[TBL] [Abstract][Full Text] [Related]
16. A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis.
Tefferi A; Lasho TL; Begna KH; Patnaik MM; Zblewski DL; Finke CM; Laborde RR; Wassie E; Schimek L; Hanson CA; Gangat N; Wang X; Pardanani A
N Engl J Med; 2015 Sep; 373(10):908-19. PubMed ID: 26332545
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF).
Mascarenhas J; Lu M; Li T; Petersen B; Hochman T; Najfeld V; Goldberg JD; Hoffman R
Br J Haematol; 2013 Apr; 161(1):68-75. PubMed ID: 23330839
[TBL] [Abstract][Full Text] [Related]
18. Psoriasis induced by interferon-alpha.
Funk J; Langeland T; Schrumpf E; Hanssen LE
Br J Dermatol; 1991 Nov; 125(5):463-5. PubMed ID: 1751354
[TBL] [Abstract][Full Text] [Related]
19. Alpha interferon treatment of patients with hairy-cell leukaemia.
Hagberg H; Alm G; Björkholm M; Glimelius B; Killander A; Simonsson B; Sundström C; Ahre A
Scand J Haematol; 1985 Jul; 35(1):66-70. PubMed ID: 4048862
[TBL] [Abstract][Full Text] [Related]
20. Interferon-alpha for idiopathic myelofibrosis.
Lancet; 1988 Apr; 1(8588):765-6. PubMed ID: 2895289
[No Abstract] [Full Text] [Related]
[Next] [New Search]
